Loading...
01/11 04:04
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call presents mixed signals. Financial performance shows moderate growth, with a slight increase in sales and adjusted net income. However, there are concerns about supply chain issues, tariff impacts, and lack of clarity in management's responses, which could weigh on investor sentiment. The absence of a shareholder return plan and the macroeconomic uncertainties further contribute to a neutral outlook. Given the company's mid-cap status, the stock is unlikely to experience significant movement, leading to a neutral prediction of -2% to 2%.
Total Sales $321,300,000, representing a year-over-year increase of 2.9% as reported and 3.8% in constant currency.
Adjusted Net Income $29,600,000, an increase of 19.6% year-over-year.
Adjusted Diluted Net Earnings per Share $0.95, an increase of 20.1% year-over-year.
Adjusted Gross Margin 56.4%, which is 80 basis points higher than the prior year quarter.
Research and Development Expense 4% of sales, 40 basis points lower than the prior year quarter.
Adjusted SG&A Expenses 38.7% of sales, consistent with the prior year.
Adjusted Interest Expense $6,800,000 in the first quarter.
Adjusted Effective Tax Rate 23.1%.
GAAP Net Income $6,000,000 compared to $19,700,000 in 2024.
GAAP Earnings per Diluted Share $0.19 this quarter compared to $0.63 a year ago.
Cash Balance $35,500,000 compared to $24,500,000 at December 31.
Accounts Receivable Days 62 days, no change from the end of 2024.
Inventory Days 222 days compared to 211 at December 31.
Long Term Debt $891,400,000 versus $905,100,000 as of December 31.
Leverage Ratio 3.2 times, which was a little better than expected.
Cash Flow from Operations $41,500,000 compared to $29,100,000 in the first quarter of 2024.
Capital Expenditures $3,800,000 compared to $2,000,000 a year ago.
BioBrace: BioBrace is being used clinically in over 50 procedures from the rotator cuff to the ACL and into the Achilles. 14 peer-reviewed publications are in print, and 9 clinical studies are underway.
New Delivery Device for BioBrace: Received FDA clearance for a new delivery device for rotator cuff repair, expected to make procedures easier and faster for surgeons.
AirSeal: AirSeal and smoke evacuation products saw double-digit demand in Q1, with a focus on clinical insufflation in robotic surgery and laparoscopy.
Sales Growth: Total sales for Q1 were $321.3 million, a 2.9% year-over-year increase, with 3.8% growth in constant currency.
Orthopedics Sales Growth: Constant currency sales growth of 3.9% in orthopedics, led by double-digit growth in foot and ankle products.
General Surgery Sales Growth: Constant currency sales growth of 3.8% in general surgery, driven by AirSeal and smoke evacuation.
Supply Chain Initiatives: Progress made in supply chain initiatives, with a decline in backordered SKUs. Expected to improve by the end of the year.
Adjusted Gross Margin: Adjusted gross margin for Q1 was 56.4%, 80 basis points higher than the prior year.
Annual Savings from Supply Chain Improvements: Expected annual savings of at least $20 million from supply chain operational improvements.
Tariff Impact: Product from the Mexico plant will be exempt from tariffs due to USMCA compliance. Estimated $5.5 million supply chain exposure in 2025 due to tariffs.
Financial Guidance: Full year revenue guidance raised to $1.35 billion - $1.378 billion, with adjusted EPS guidance increased to $4.45 - $4.60.
Supply Chain Challenges: The company acknowledges ongoing supply chain issues, with some SKUs on backorder declining but not yet at desired levels. They expect to be in a better position by the end of the year.
Tariff Exposure: The company estimates approximately $5,500,000 of supply chain exposure in 2025 due to tariffs, with 80% from China. This translates to an estimated EPS impact of $0.14, with $0.02 hitting Q3 and $0.12 hitting Q4.
Macroeconomic Uncertainty: Management noted that the macroeconomic and policy backdrop creates uncertainty for customers, although demand for products remains strong.
Competitive Pressures: The company is closely tracking customer spending patterns but has not observed any material changes, indicating a stable demand environment despite potential competitive pressures.
Regulatory Issues: The company is compliant with USMCA, which exempts products from their Mexico plant from tariffs, mitigating some tariff-related risks.
Operational Improvements: While operational improvements are expected to yield at least $20,000,000 in annual savings, these benefits will not materialize until 2026.
Sales Growth: Total sales for Q1 were $321.3 million, a 2.9% year-over-year increase, exceeding guidance.
Product Development: BioBrace is being used in over 50 procedures and has 14 peer-reviewed publications. FDA clearance received for a new delivery device for rotator cuff repair.
Supply Chain Initiatives: Progress made in supply chain operations, with a decline in backordered SKUs. Expected improvements by year-end.
Growth Drivers: Focus on four growth platforms: AirSeal, BioBrace, Buffalo Filter, and Convent Foot and Ankle.
Revenue Guidance: Full year revenue guidance raised to $1.35 billion - $1.378 billion, reflecting a constant currency growth of 4-6%.
EPS Guidance: Adjusted EPS guidance increased to $4.45 - $4.60, up from $4.25 - $4.40.
Margin Expectations: Expected adjusted gross margins for Q2 in the mid-56% range, Q3 in the mid-55% range, and Q4 approaching 57%.
Tariff Impact: Estimated tariff exposure of $5.5 million for 2025, with $0.14 impact on EPS.
Shareholder Return Plan: The company has not announced any specific share buyback or dividend program during the call.
The earnings call presents a mixed picture: while there is a slight increase in EPS and cash flow, there are concerns about declining gross margins, a significant drop in GAAP net income, and management's reluctance to provide future guidance. The leverage ratio improvement and AirSeal's growth are positives, but the orthopedic backlog and tariff impacts are negatives. The market cap suggests moderate volatility, leading to a neutral stock price prediction.
The earnings call shows a positive sentiment due to strong financial performance, increased revenue and EPS guidance, and operational improvements. Despite high debt levels and market competition, the company is making progress in supply chain and innovation. The Q&A section confirms stable market conditions and legislative support for growth. The market cap indicates a moderate reaction, leading to a prediction of a positive stock price movement (2% to 8%) over the next two weeks.
The earnings call presents a mixed outlook. While there are positive aspects such as increased adjusted EPS guidance and revenue growth, challenges like supply chain issues and tariff impacts persist. The Q&A section reveals management's confidence but also a lack of clarity on certain issues. The company's financials show moderate growth and improvements, but the absence of a share repurchase program and macroeconomic uncertainties add caution. Given the company's moderate market cap, these factors suggest a neutral stock price movement over the next two weeks.
The earnings call presents mixed signals. Financial performance shows moderate growth, with a slight increase in sales and adjusted net income. However, there are concerns about supply chain issues, tariff impacts, and lack of clarity in management's responses, which could weigh on investor sentiment. The absence of a shareholder return plan and the macroeconomic uncertainties further contribute to a neutral outlook. Given the company's mid-cap status, the stock is unlikely to experience significant movement, leading to a neutral prediction of -2% to 2%.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
